An introduction to biologics and biosimilars. Part I: Biologics: What are they and where do they come from?

Canadian Pharmacists Journal

Volumn 143, Issue 3, 2010, Pages 134-139

  Revers, Leigh ^a   Furczon, Eva ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADALIMUMAB; AMINO ACID; BEVACIZUMAB; BIOLOGICS; BLOOD CLOTTING FACTOR 7A; CETUXIMAB; DACLIZUMAB; DIGOXIN; ECULIZUMAB; EFALIZUMAB; ERYTHROPOIETIN; HUMAN INSULIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NATALIZUMAB; NATURAL PRODUCT; OKT 3; OMALIZUMAB; ORTHOCLONE; PACLITAXEL; PENICILLIN G; QUININE; RANIBIZUMAB; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; SALICIN; TOCILIZUMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; DIABETES MELLITUS; DRUG APPROVAL; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MICROORGANISM; MOLECULAR WEIGHT; NONHUMAN; PANCREAS ISLET; PLASMA;

EID: 77956550092     PISSN: 17151635     EISSN: None     Source Type: Journal    
DOI: 10.3821/1913-701X-143.3.134     Document Type: Article

References (27)

1. Ropp KL. Just what is a biologic, anyway? FDA Consumer 1993;27(3).
2. Covic A, Kuhlmann M. Biosimilars: recent developments. Int Urol Nephrol 2007;39(1):261-6.
3. Protein Data Bank. A resource for studying biological macromolecules. Available: www.pdb.org/pdb/home/home.do (accessed May 4, 2009).
4. Waldman TA. Immunotherapy: past, present and future. Nat Med 2003;9(3):269-77.
5. Plotkin SA. Vaccines: past, present and future. Nat Med 2005;11 Supp 4:S5-11.
6. Gricks C, Cann CI, Merrin A. Antibody therapies in oncology. Waltham (MA): Decision Resources, Inc.; Jun 2008.
7. Westphal NJ, Malecki MJ. Biosimilars 2007-2017: shifting payer and physician opinion increases the hurdles to uptake. Waltham (MA): Decision Resources, Inc.; 2008.
8. Biotechnology Institute. Historical events in biotechnology. Available: www.biotechinstitute.org/what_is/timeline.html (accessed May 2, 2009).
9. Nobelprize.org. Emil von Behring: the founder of serum therapy. 2001 Dec 3. Available: http://nobelprize.org/nobel_prizes/ medicine/articles/behring/index.html (accessed May 11, 2009).
10. Glassman RH, Sun AY. Biotechnology: identifying advances from the hype. Nat Rev Drug Discov 2004;3(2):177-83.
11. Sneader W. History of insulin. Encyclopedia of life sciences.2001 April 25. Available: http://mrw.interscience.wiley.com/emrw/9780470015902/els/article/a0003623/current/abstract?hd=All,w&hd=All,sneader (accessed March 11, 2010).
12. Rosenfeld L. Insulin: discovery and controversy. Clin Chem 2002;48(12):2270-88.
13. Strettona AO. The fi rst sequence: Fred Sanger and insulin. Genetics 2002;162(2):527-32.
14. Cohen SN, Chang AC, Boyer HW, Helling RB. Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci USA 1973;70(11):3240-4.
15. Goeddel DV, Levinson AD. Obituary: Robert A. Swanson (1947-99). Nature 2000;403(6767):264.
16. Abate T. The birth of biotech: how the germ of an idea became the genius of Genentech. San Francisco Chronicle. 2001 April 1. Available: http://articles.sfgate.com/2001-04-01/business/17593472_1_herb-boyer-genentech-s-south-san-francisco-bay-area (accessed April 23, 2009).
17. Eli Lilly & Company. Annual report. Indianapolis (IN): Eli Lilly & Company; 2008.
18. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007;78(3):183-205.
19. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252(15):5558-64.
20. Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985;116(6):2293-9.
21. Smith S. Ten years of Orthoclone OKT3 (muromonab- CD3): a review. J Transpl Coord 1996;6(3):109-19.
22. Kaufmann SH. Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol 2008;9(7):705-12.
23. Steiner LA. Rodney Robert Porter (1917-1985). Nature 1985;317(6036):383.
24. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256(5517):495-7.
25. Ezzell C. Magic bullets fly again. Sci Am 2001;285(4):34-41.
26. Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 2010;40(2):122-35.
27. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009;9(11):1445-51.